Pharmacologic and molecular discrimination of I2-imidazoline receptor subtypes.
I2-imidazoline receptors (I2-IR) are characterized by their high affinity for imidazolines and guanidines and medium affinity for imidazolidines. The differential recognition of I2-IR by amiloride led to subtype these sites as amiloride-sensitive (I2A-IR) and amiloride-insensitive (I2B-IR). I2-IR labeled with [3H]idazoxan or [3H]2-BFI in the rabbit cerebral cortex (I2A-IR) displayed higher affinities for amiloride and amiloride analogs than in the rat cerebral cortex (I2B-IR). Other drugs tested displayed biphasic curves in competition experiments, indicating the existence of high and low affinity sites for both I2-IR subtypes. The drugs (+)- and (-)-medetomidine, bromoxidine, moxonidine, and clorgyline were more potent on the high and/or low affinity sites of I2B-IR than on I2A-IR. Preincubation (30 min at 25 degrees C) with 10(-6) M isothiocyanatobenzyl imidazoline (IBI) or with 10(-6) M clorgyline reduced by 40% and 26%, respectively, the binding of [3H]2-BFI to I2B-IR, but it did not alter the binding of the radioligand to I2A-IR. These results indicated that the I2-IR subtypes differ in their pharmacologic profiles and in the nature of the imidazoline binding site involved in clorgyline and IBI alkylation. In rat cortical membranes, western blot detection of immunoreactive imidazoline receptor proteins revealed a double band of approximately 29/30 kD and three less intense bands of approximately 45, approximately 66, and approximately 85 kD. In rabbit cortical membranes the antibody detected proteins of approximately 30, approximately 57, approximately 66, and approximately 85 kD. It is suggested that I2-IR may be related to more than one receptor protein and that I2-IR subtypes differ in the nature of the proteins implicated.
Institute of Neurobiology Ramón y Cajal, CSIC, Department of Biology, University of the Balearic Islands, Palma de Mallorca, Spain.
G
G
Olmos
R
R
Alemany
M A
MA
Boronat
J A
JA
García-Sevilla
D000584:Amiloride / Q000031:analogs & derivatives / Q000493:pharmacokinetics / Q000494:pharmacology; D000818:Animals; D001572:Benzofurans / Q000493:pharmacokinetics*; D002462:Cell Membrane / Q000378:metabolism; D002540:Cerebral Cortex / Q000378:metabolism*; D019791:Guanidine / Q000493:pharmacokinetics; D019329:Idazoxan / Q000493:pharmacokinetics*; D007093:Imidazoles / Q000493:pharmacokinetics*; D054755:Imidazoline Receptors; D008297:Male; D008996:Monoamine Oxidase Inhibitors / Q000493:pharmacokinetics; D011817:Rabbits; D011869:Radioligand Assay; D051381:Rats; D017207:Rats, Sprague-Dawley; D011955:Receptors, Drug / Q000145:classification / Q000187:drug effects / Q000378:metabolism*; D014316:Tritium
D001572:Benzofurans; D007093:Imidazoles; D054755:Imidazoline Receptors; D008996:Monoamine Oxidase Inhibitors; D011955:Receptors, Drug; D014316:Tritium; C103723:2-(2-benzofuranyl)-2-imidazoline; D000584:Amiloride; D019791:Guanidine; D019329:Idazoxan